"if" you are right with your views on AMRN, then I think at some point BP would want to take advantage of the situation. I do hope you will share with us any stories you may have of patients on Vascepa, if any. Thanks.
Thanks for your opinion and insight; please take the time to contribute your thoughts Re: Vascepa and sales after top line R-I results. For example, if "V" only shows a paltry Vytorin RRR ~7% vs. a Crestor RRR ~ 40%?
Considering the safety profile I think sales still reach $1 billion per year with ~7% RRR due to safety & value.
If "V" hits a JUPITOR homer (like I expect), "V" sells >> $10 billion per year just in US.
Market Data 
Markets 
AI
